FDA approves Enhertu for metastatic breast cancer with HER2-low or HER2-ultralow expression after showing significant ...

Just 11 days after AstraZeneca and Daiichi Sankyo gained FDA approval | The FDA has cleared AstraZeneca and Daiichi Sankyo's ...

Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY) announced Friday that an expert panel of the EU drug regulator, the European ...

AstraZeneca (AZ) and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved by the US Food and Drug ...

Approval of Enhertu marks the first HER2-directed therapy indicated for adults with unresectable or metastatic HR-positive, ...

Enhertu’s label expansion comes on the heels of the FDA’s approval of the partners' Datroway for a related type of breast ...

The FDA approves AstraZeneca's sBLA for Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer in the United ...

Roche has secured a new FDA approval for its first companion diagnostic test aimed at identifying breast cancer patients with ...

New approval brings the medicine to an earlier treatment setting and a broader patient population.

Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief ...

The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.

Daiichi Sankyo (OTCPK ... as a late-line option for certain cases of breast cancer. Issuing a so-called positive opinion, EMA’s Committee for Medicinal Products for Human Use (CHMP) has ...